CIK 0001501796 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Net income (USD) | -106.2 M | -76.4 M | -58.8 M |
| Diluted EPS (USD/shares) | -1.76 | -1.93 | -1.96 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-01 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-09-01 | 4 | 4 | 2026-09-01 |
| 2026-09-01 | 4 | 4 | 2026-09-01 |
| 2026-09-01 | 4 | 4 | 2026-09-01 |
| 2026-09-01 | 4 | 4 | 2026-09-01 |
| 2026-09-01 | 4 | 4 | 2026-09-01 |
| 2026-09-01 | S-8 | S-8 | |
| 2026-08-20 | EFFECT | EFFECT items ,, | |
| 2026-08-18 | CORRESP | CORRESP | |
| 2026-08-17 | UPLOAD | UPLOAD | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-12 | 3 | 3 | 2026-08-12 |
| 2026-08-12 | 3 | 3 | 2026-08-10 |
| 2026-08-12 | 3 | 3 | 2026-08-10 |
| 2026-08-12 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-11 | S-3 | S-3 | |
| 2026-08-11 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-11 | 8-K | 8-K items 2.02,2.05,5.02,8.01,9.01 | 2026-08-11 |
| 2026-08-05 | 8-K | 8-K items 5.07 | 2026-08-05 |
| 2026-07-27 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-08 | 4 | 4 | 2026-07-07 |
| 2026-07-08 | 3 | 3 | 2026-07-07 |
| 2026-07-08 | 8-K | 8-K items 5.02,9.01 | 2026-07-03 |
| 2026-07-01 | 4 | 4 | 2026-07-01 |
Forms on file (last 1,000): 4 112, 8-K 52, 144 44, 3 24, 10-Q 15, SCHEDULE 13G/A 13, SC 13G/A 12, D 11. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=AURA (0.002 USD), /gw/filings/filings?ticker=AURA&form=8-K, /gw/filings/facts?ticker=AURA&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange